159 related articles for article (PubMed ID: 38280061)
1. Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy - a supplementary analysis of JCOG0601.
Shimada K; Ohmachi K; Machida R; Ota S; Itamura H; Tsujimura H; Takayama N; Shimada T; Kurosawa M; Tabayashi T; Shimoyama T; Ohshima K; Miyazaki K; Maruyama D; Kinoshita T; Ando K; Hotta T; Tsukasaki K; Nagai H
Ann Hematol; 2024 Jun; 103(6):2021-2031. PubMed ID: 38280061
[TBL] [Abstract][Full Text] [Related]
2. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
3. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
[TBL] [Abstract][Full Text] [Related]
4. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
[TBL] [Abstract][Full Text] [Related]
5. Central Nervous System International Prognostic Index Impacts Overall Survival in Diffuse Large B-cell Lymphoma Treated with R-Chop in a third Level Cancer Center from Mexico: A Survey of 642 Patients.
Solís-Armenta R; Cacho-Díaz B; Gutiérrez-Hernández O; Candelaria-Hernández M
Rev Invest Clin; 2021 Apr; 73(4):231-237. PubMed ID: 33845484
[TBL] [Abstract][Full Text] [Related]
6. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.
Gleeson M; Counsell N; Cunningham D; Chadwick N; Lawrie A; Hawkes EA; McMillan A; Ardeshna KM; Jack A; Smith P; Mouncey P; Pocock C; Radford JA; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Ann Oncol; 2017 Oct; 28(10):2511-2516. PubMed ID: 28961838
[TBL] [Abstract][Full Text] [Related]
7. Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse.
Oka S; Ono K; Nohgawa M
Pathol Oncol Res; 2020 Jul; 26(3):1843-1850. PubMed ID: 31768966
[TBL] [Abstract][Full Text] [Related]
8. Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
Eyre TA; Kirkwood AA; Wolf J; Hildyard C; Mercer C; Plaschkes H; Griffith J; Fields P; Gunawan A; Oliver R; Booth S; Martinez-Calle N; McMillan A; Bishton M; Fox CP; Collins GP; Hatton CSR
Br J Haematol; 2019 Oct; 187(2):185-194. PubMed ID: 31222719
[TBL] [Abstract][Full Text] [Related]
9. Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era?
Deng L; Song Y; Zhu J; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Ying Z; Liu W; Zhang C
Int J Hematol; 2013 Dec; 98(6):664-71. PubMed ID: 24234713
[TBL] [Abstract][Full Text] [Related]
10. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
11. Diffuse large B-cell lymphoma: A retrospective study from a regional care center in South India.
Babu SM; Garg S; Kanakasetty GB; Kuntegowdanahalli LC; Dasappa L; Rao SA
Indian J Cancer; 2018; 55(1):66-69. PubMed ID: 30147096
[TBL] [Abstract][Full Text] [Related]
12. Extranodal site of diffuse large B-cell lymphoma and the risk of R-CHOP chemotherapy resistance and early relapse.
Ting CY; Gan GG; Bee-Lan Ong D; Tan SY; Bee PC
Int J Clin Pract; 2020 Oct; 74(10):e13594. PubMed ID: 32583545
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.
Villa D; Connors JM; Shenkier TN; Gascoyne RD; Sehn LH; Savage KJ
Ann Oncol; 2010 May; 21(5):1046-52. PubMed ID: 19861575
[TBL] [Abstract][Full Text] [Related]
14. Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.
Yoo C; Kim S; Sohn BS; Kim JE; Yoon DH; Huh J; Lee DH; Kim SW; Lee JS; Suh C
Korean J Intern Med; 2010 Sep; 25(3):301-8. PubMed ID: 20830228
[TBL] [Abstract][Full Text] [Related]
15. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
McMillan AK; Phillips EH; Kirkwood AA; Barrans S; Burton C; Rule S; Patmore R; Pettengell R; Ardeshna KM; Lawrie A; Montoto S; Paneesha S; Clifton-Hadley L; Linch DC
Ann Oncol; 2020 Sep; 31(9):1251-1259. PubMed ID: 32464282
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system involvement in diffuse large B-cell lymphoma.
Yamamoto W; Tomita N; Watanabe R; Hattori Y; Nakajima Y; Hyo R; Hashimoto C; Motomura S; Ishigatsubo Y
Eur J Haematol; 2010 Jul; 85(1):6-10. PubMed ID: 20236301
[TBL] [Abstract][Full Text] [Related]
18. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.
El-Galaly TC; Villa D; Michaelsen TY; Hutchings M; Mikhaeel NG; Savage KJ; Sehn LH; Barrington S; Hansen JW; Smith D; Rady K; Mylam KJ; Larsen TS; Holmberg S; Juul MB; Cordua S; Clausen MR; Jensen KB; Johnsen HE; Seymour JF; Connors JM; de Nully Brown P; Bøgsted M; Cheah CY
Eur J Cancer; 2017 Apr; 75():195-203. PubMed ID: 28237865
[TBL] [Abstract][Full Text] [Related]
19. Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system.
Yoon SE; Kim WS; Kim SJ
Korean J Intern Med; 2020 Jul; 35(4):946-956. PubMed ID: 31752477
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.
Hui D; Proctor B; Donaldson J; Shenkier T; Hoskins P; Klasa R; Savage K; Chhanabhai M; Gascoyne RD; Connors JM; Sehn LH
Leuk Lymphoma; 2010 Sep; 51(9):1658-67. PubMed ID: 20795790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]